首页> 美国卫生研究院文献>The Journal of Biological Chemistry >Development of a Human IgG4 Bispecific Antibody for Dual Targeting of Interleukin-4 (IL-4) and Interleukin-13 (IL-13) Cytokines
【2h】

Development of a Human IgG4 Bispecific Antibody for Dual Targeting of Interleukin-4 (IL-4) and Interleukin-13 (IL-13) Cytokines

机译:人IgG4双特异性抗体对白介素4(IL-4)和白介素13(IL-13)细胞因子双重靶向的开发。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Human bispecific antibodies have great potential for the treatment of human diseases. Although human IgG1 bispecific antibodies have been generated, few attempts have been reported in the scientific literature that extend bispecific antibodies to other human antibody isotypes. In this paper, we report our work expanding the knobs-into-holes bispecific antibody technology to the human IgG4 isotype. We apply this approach to generate a bispecific antibody that targets IL-4 and IL-13, two cytokines that play roles in type 2 inflammation. We show that IgG4 bispecific antibodies can be generated in large quantities with equivalent efficiency and quality and have comparable pharmacokinetic properties and lung partitioning, compared with the IgG1 isotype. This work broadens the range of published therapeutic bispecific antibodies with natural surface architecture and provides additional options for the generation of bispecific antibodies with differing effector functions through the use of different antibody isotypes.
机译:人双特异性抗体具有治疗人类疾病的巨大潜力。尽管已经产生人IgG1双特异性抗体,但是在科学文献中几乎没有报道尝试将双特异性抗体扩展至其他人抗体同种型。在本文中,我们报告了我们的工作,将多节成孔双特异性抗体技术扩展至人IgG4同种型。我们应用这种方法来生成针对IL-4和IL-13的双特异性抗体,IL-4和IL-13是在2型炎症中起作用的两种细胞因子。我们显示,与IgG1同种型相比,IgG4双特异性抗体可以以等效的效率和质量大量产生,并且具有可比的药代动力学特性和肺分配。这项工作拓宽了已公开的具有天然表面结构的治疗性双特异性抗体的范围,并为通过使用不同的抗体同种型产生具有不同效应子功能的双特异性抗体提供了更多选择。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号